Please login to the form below

Not currently logged in
Email:
Password:

talimogene laherparepvec

This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.

Amgen and Merck to expand cancer collaboration

Amgen and Merck to expand cancer collaboration

Amgen and Merck have expanded their collaboration to evaluate the efficacy and safety of Amgen's talimogene laherparepvec in combination with Merck's Keytruda. ... Talimogene laherparepvec and Keytruda are designed to result in anti-tumour immune

Latest news

  • FDA gives priority review for Keytruda in lung cancer FDA gives priority review for Keytruda in lung cancer

    Earlier, the company also signed an expanded deal to test Amgen's oncolytic virus therapy talimogene laherparepvec with Keytruda in head and neck cancer.

  • AZ and BMS earn ASCO plaudits AZ and BMS earn ASCO plaudits

    Big pharma deals. Meanwhile, Amgen has announced a tie-up with Roche w ith the two firms' investigational medicines talimogene laherparepvec and atezolizumab. ... Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to

  • Amgen’s immuno-oncology drug scores in skin cancer Amgen’s immuno-oncology drug scores in skin cancer

    Amgen's investigational cancer drug Talimogene Laherparepvec has improved response rates in patients with advanced and difficult-to-treat melanoma. ... Talimogene Laherparepvec (or T-Vec), which works as an investigational oncolytic immunotherapy, was

  • FDA panel backs Amgen's T-Vec for melanoma FDA panel backs Amgen's T-Vec for melanoma

    The panel voted 22 to one in favour of approving T-Vec (talimogene laherparepvec) on the strength of the phase III OPTiM study, which found that the response rate to the

  • Amgen banking on three launches in 2015 Amgen banking on three launches in 2015

    year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma.

More from news
Approximately 4 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clinigen

Clinigen Global Access Programs specializes in the consultancy, development, management and implementation of access programs across the product lifecycle for...

Latest intelligence

The vitamin D deficiency: should we act?
Healthcare PR agency Say Communications analyses whether headlines are able to trigger a behavioural change with regards to the vitamin D deficiency issue....
Is obesity the new smoking?
Is obesity the new smoking? The healthcare PR team at Say communications analyses the question posed by NHS Chief executive Simon Stevens....
Children, the weight issue and how we deal with this responsibly?
Say Communication, Healthcare PR Agency, looks at how children deal with the weight issue and how we can approach it responsibly....

Infographics